Private Equity Investors, Inc. is a private equity and venture capital firm specializing in fund of funds and secondary acquisitions in secondary indirect investments. Within direct, it prefers to invest in mature and late ventures. For fund of funds investments, it seeks to invest in venture capital, growth equity, private equity, leveraged buyout & mezzanine funds and manages funds-of-funds that invest in venture capital, growth equity, and buyout funds at the time of their origination. It seeks to purchase limited partnership interests, portfolios of direct private holdings, fund restructurings, financial institutions or corporate spin-outs, and all the assets of a fund or fund of funds. Within the secondary transactions that the firm makes to general partners of mature funds and fund of funds, it provides fund or fund of funds wind down, asset purchase, tender offers, and restructuring solutions. Within the secondary transactions, the firm provides cash purchase, purchase of non strategic holdings, and restructuring to corporate venture programs. The firm also provides liquidity to limited partners of private equity funds and to investors with portfolios of direct holdings. It prefers to invest in logistics and retail, communications, and healthcare. It invests in funds investing in broadly diversified sectors including biotechnology, consumer or retail, financial, healthcare, industrial, materials, media or communications, and technology. It seeks investments across the United States and overseas while investing in other funds. It seeks to make investments in interest with asset value between $1 million and $25 million. The firm typically acquires limited partnership interests in transactions with values ranging between $1 million and $100 million, but typically looks at transactions with less than $50 million in value and $30 million in net asset value. It invests between $1 million & $30 million. Private Equity Investors, Inc. was founded in 1992 and is based in New York, New York with additional offices in Chicago, Illinois; San Francisco, California; and Tokyo, Japan.

Phoenix Equity Partners is a London-based private equity and venture capital firm founded in 2001, with an additional office in Manchester. It specializes in mid-market investments across various sectors in the UK, focusing on management buyouts, growth capital, and expansion transactions. The firm typically invests between $16 million and $80 million in private medium-sized companies with enterprise values ranging from $16 million to $345.5 million. Phoenix targets sectors including education, healthcare, industrials, consumer products, financial services, and business services, among others. The firm aims to acquire significant stakes in its portfolio companies and generally seeks a board seat to actively participate in management. Phoenix prefers to hold its investments for three to five years, providing follow-on capital to support growth initiatives and strategic acquisitions.

Elderstreet is a leading UK venture capital fund manager investing in early stage and development capital for UK growing businesses. They provide funding for growth and development capital in most industry sectors with investments typically in the range of £2m to £10m by syndicating their VCT funds alongside Draper Esprit funds. Draper Esprit is one of the leading venture capital investors involved in the creation, funding and development of high-growth technology businesses with an emphasis on digital technologies in the UK, the Republic of Ireland and Europe. Draper Esprit floated on the AIM market in June 2016 and has a market capitalisation of over £200 million.

Zero2IPO, founded in 1999, is a prominent integrated service provider in China's venture capital and private equity sector. The firm has established itself as a key source of deal flow and networking opportunities within the industry. With its headquarters in Beijing and additional offices in Shanghai, Shenzhen, Hong Kong, and Silicon Valley, Zero2IPO aims to be the preferred partner for businesses in this field, offering extensive knowledge and expertise to clients and partners. The company provides a wide range of services designed to support entrepreneurs and investors in achieving their goals. Additionally, Zero2IPO operates several investment subsidiaries, including Zero2IPO Ventures, Zero2IPO Capital, and Zero2IPO Investment, which invest and manage funds independently.

Zero2IPO Ventures is the venture investment arm under Zero2IPO Group targeted at high-potential, high-growth China enterprises. Leveraging Zero2IPO's vast network in China, Zero2IPO Ventures does not compete with other venture funds, but rather pursue a two-prong investment strategy, i.e. to co-invest with active venture capital firms in growth and late stage companies and to lead or co-lead in early stage startups in China. The industry focus includes Internet, mobile and wireless applications, digital media, healthcare, green-tech, consumable products and services, as well as other emerging sectors. We intend to leverage the extensive network that has been created by Zero2IPO Group, a leading venture capital and private equity market research and financial advisory company, to seek out potential investment opportunities and provide a strong value-add to our portfolio companies. Through its venture capital and private equity surveys, investment forums, training programs, and investment advisory services, Zero2IPO Group has developed a strong reputation in the China market for helping entrepreneurs connect with investors.

Investible matches the world's brightest founders with the smartest capital, using our unique investor and business-development IP to identify, cultivate, invest and support startups. We invest early and support actively, with a framework that enables high-potential founders to realise their vision.

Share Capital is a venture capital firm specializing in seed, start-up, early, middle, growth capital, and Pre-IPO investments. it primarily invests in big living, medical healthcare, and internet innovation. In medical healthcare, it seeks to invests in pharmaceuticals, innovative equipment, biotechnology, diagnostic testing equipment and reagents, anti-infectives, drug discovery, medical health service, mobile medical services, and informatization.